APLMApollomics
About Apollomics
Apollomics (NASDAQ:APLM) focuses on the discovery, development, and commercialization of oncology treatments and therapies, aiming to reshape the landscape of cancer care. The company is devoted to advancing a robust pipeline of novel therapeutic compounds, including targeted approaches for various cancers, leveraging cutting-edge research and technology. With projects ranging from early-stage discovery to clinical development, Apollomics seeks to improve outcomes for patients battling this challenging disease. The objective is to deliver innovative solutions that address unmet medical needs, transforming how cancer is treated and offering hope to patients and their families.
What is APLM known for?
Snapshot
Public US
Ownership
2015
Year founded
45
Employees
Foster City, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Produtos e/ou serviços de Apollomics
- Cancer Drug Discovery & Development: Apollomics focuses on creating new drugs for cancer treatment. They identify potential targets and develop drug candidates through preclinical and clinical trials.
- Immuno-oncology Focus: Their research leans towards leveraging the body's immune system to fight cancer.
- Clinical Trial Pipeline Management: They manage a pipeline of drug candidates undergoing clinical trials to assess safety and effectiveness.
- Collaboration Potential: Apollomics may collaborate with other pharmaceutical companies for further development or licensing of their drugs.
- Partnerships for Development: They might partner with other organizations to expedite research or clinical trials.
- Intellectual Property Portfolio Building: As they develop drugs, Apollomics builds a portfolio of intellectual property to protect their innovations.
equipe executiva do Apollomics
- Mr. Hung-Wen ChenCEO & Chairman of the Board
- Mr. K. H. Lin C.A.I.A., M.B.A.Chief Financial Officer
- Mr. Yi-Kuei ChenDirector & COO